Patents by Inventor Kevin B. Clairmont

Kevin B. Clairmont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
    Patent number: 7494978
    Abstract: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: February 24, 2009
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Clark Pan, James Whelan, Kevin B. Clairmont
  • Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
    Patent number: 7488716
    Abstract: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: February 10, 2009
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Clark Pan, James Whelan, Kevin B. Clairmont
  • Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
    Patent number: 7488714
    Abstract: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: February 10, 2009
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Clark Pan, James Whelan, Kevin B. Clairmont
  • Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
    Patent number: 7488715
    Abstract: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: February 10, 2009
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Clark Pan, James Whelan, Kevin B. Clairmont
  • Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
    Patent number: 7399745
    Abstract: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
    Type: Grant
    Filed: November 29, 2004
    Date of Patent: July 15, 2008
    Assignee: Bayer HealthCare LLC
    Inventors: Clark Pan, James Whelan, Kevin B. Clairmont
  • Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
    Patent number: 7041646
    Abstract: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: May 9, 2006
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Clark Pan, James Whelan, Kevin B. Clairmont
  • Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
    Patent number: 6864069
    Abstract: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: March 8, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Clark Pan, James Whelan, Kevin B. Clairmont
  • Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
    Publication number: 20040002442
    Abstract: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
    Type: Application
    Filed: January 16, 2003
    Publication date: January 1, 2004
    Inventors: Clark Pan, James Whelan, Kevin B. Clairmont
  • Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
    Publication number: 20030124669
    Abstract: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
    Type: Application
    Filed: October 3, 2002
    Publication date: July 3, 2003
    Inventors: Clark Pan, James Whelan, Kevin B. Clairmont
  • Glucose transporter vesicle aminopeptidase
    Patent number: 5972680
    Abstract: An aminopeptidase which is a component of GLUT4-containing vesicles in the natural state, and which cleaves insulin. The claimed protein has an apparent molecular weight of approximately 110 kD in its deglycosylated form and a predicted molecular weight of 117,239 Daltons. It includes the amino acid sequences Phe-Ala-Ala-Thr-Gln-Phe-Glu-Pro-Leu-Ala-Ala (SEQ ID NO: 1) and Ile-Leu-Gln-Asn-Gln-Ile-Gln-Gln-Gln-Thr-Arg-Thr-Asp-Glu-Gly-Xaa-Pro-Xaa-Me t (SEQ ID NO: 2, and reacts with antibodies produced against the peptide identified as (SEQ ID NO: 1). It is encoded by the cDNA of FIG. 20 (SEQ. ID NOs. 15 and 16) and is essentially the protein sequence therein described. Modulators of the activity of the aminopeptidase and a method for treating syndromes of insulin resistance, including diabetes, by administration of such a modulator are also claimed.
    Type: Grant
    Filed: September 19, 1995
    Date of Patent: October 26, 1999
    Assignee: Bayer Corporation
    Inventors: William J. Knowles, Donna Guralski, John T. Letsinger, Wallace Haigh, John T. Hart, Kevin B. Clairmont